GleamWall
中文EN

CRBP Corbus Pharmaceuticals Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1595097 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-72.3%
TTM EPS YoY-10.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-131.5%
ROA-100.1%
ROIC (approx.)-160.1%
Asset turnover—

Leverage & solvency

Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-20.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$34.25M$31.18M$19.82M$18.41M$20.86M$15.19M$15.64M$8.79M
SG&A expense$4.58M$5.01M$4.49M$3.56M$3.56M$3.96M$4.13M$3.82M
Operating income-$38.82M-$36.19M-$24.30M-$21.97M-$24.42M-$19.15M-$19.77M-$12.61M
Interest expense———$0$0$0$0$0
Net income-$37.75M-$35.04M-$22.97M-$20.55M-$23.34M-$17.66M-$16.98M-$9.53M
EBITDA-$38.72M-$36.14M-$24.25M-$21.92M-$24.32M-$19.05M-$19.69M-$12.47M
EPS (basic)-1.81-1.81-1.23—-1.90-1.44-1.39—
EPS (diluted)-1.81-1.81-1.23—-1.90-1.44-1.39—
Weighted avg. shares (diluted)20.84M19.41M18.71M—12.31M12.24M12.20M—
Balance sheet
Cash & equivalents$30.25M$23.37M$25.66M$28.49M$26.98M$20.04M$18.90M$17.20M
Short-term investments$85.09M$94.57M$112.56M$134.78M$77.00M$96.55M$113.89M$131.86M
Current assets$118.95M$122.75M$143.57M$166.95M$107.57M$122.83M$137.36M$152.98M
PP&E, net$36,000$71,000$116,000$159,000$201,000$251,000$304,000$385,000
Total assets$122.90M$126.99M$144.48M$168.19M$109.51M$125.08M$139.93M$155.88M
Current liabilities$34.97M$21.48M$18.14M$20.69M$17.06M$13.33M$11.62M$11.82M
Total liabilities$38.14M$24.75M$18.14M$20.69M$17.37M$14.09M$12.82M$13.45M
Shareholders' equity$84.76M$102.24M$126.34M$147.50M$92.15M$110.99M$127.11M$142.43M
Shares outstanding20.61M18.67M17.74M17.61M12.53M12.25M12.23M12.18M
Cash flow statement
Operating cash flow-$21.24M-$29.63M-$25.57M-$15.92M-$15.55M-$16.60M-$16.42M-$10.94M
Capital expenditure$15,000$6,000$6,000$7,000$0$0$0—
Free cash flow-$21.25M-$29.63M-$25.58M-$15.93M-$15.55M-$16.60M-$16.42M—
Investing cash flow$9.56M$18.26M$22.45M-$57.15M$19.64M$17.74M$18.12M$8.73M
Financing cash flow$18.55M——$74.58M$2.85M$0$0-$13,000
Depreciation & amortization$100,000$50,000$49,000$49,000$100,000$100,000$81,000$134,000
Stock-based compensation$1.81M$1.81M$1.92M$1.43M$1.58M$1.56M$1.71M$1.63M

Free plan shows the latest 8 periods; Pro shows all 53 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.